---
schema_version: "secwatch.filing_event.v1"
accession: "0001034842-26-000005"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:46:03.774987+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Rigel Pharmaceuticals Provides Preliminary Q4 2025 Revenue of $69.8M and 2026 Outlook of $275-290M

## Summary
- Preliminary Q4 2025 total revenue $69.8M, net product sales $65.4M, vs $57.6M and $46.5M in Q4 2024.
- Full year 2025 total revenue $294.3M, net product sales $232.0M, up 60% from 2024.
- 2026 outlook: total revenue $275-290M, net product sales $255-265M, positive net income expected.
- R289 Phase 1b study: RBC-TI achieved by 33% (6/18) evaluable patients at doses ≥500 mg QD; enrollment on track for RP2D selection H2 2026.
- FDA approved boxed warning for GAVRETO (pralsetinib) for serious infections; postmarketing commitment met.

## SEC filing metadata
- accession: 0001034842-26-000005
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000005/0001034842-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000005/rigl-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001034842-26-000005
- JSON: https://secwatch.observer/filing/0001034842-26-000005.json
- Plain text: https://secwatch.observer/filing/0001034842-26-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.